Tadalafil is a PDE5 inhibitor indicated for erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension. We supply it to US manufacturers of tablets and oral suspension.
Data from PubChem (CID 110635) and FDA’s substance registry
CAS number
171596-29-5
Molecular formula
C22H19N3O4
Molecular weight
389.4g/mol
FDA UNII
IUPAC name
(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
InChIKey
WOXKDUGGOYFFRN-IIBYNOLFSA-N
- Appearance
- White or almost white powder.
- Solubility
- Practically insoluble in water, freely soluble in dimethyl sulfoxide and slightly soluble in methylene chloride.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Micronized material is standard. It has two chiral centers, so check the limits for the other stereoisomers.
On the US market
- Reference product
- CialisNDA 021368
- Approved ANDAs
- 39 with a marketed product
- Approved forms and strengths
- Tablet 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg
- Oral suspension 20 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com